08:29 AM EDT, 09/08/2025 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) said Monday claseprubart demonstrated statistically significant and clinically meaningful improvements in a phase 2 study of adults with acetylcholine receptor antibody positive generalized myasthenia gravis.

The therapy improved daily living and muscle strength scores as early as the first week and maintained benefits through week 13, the company said.

Both 300 mg and 600 mg doses were comparable across key efficacy endpoints, supporting development of a single 300 mg self-injector given once every two weeks, Dianthus said.

Claseprubart was generally well tolerated with no drug-related serious adverse events or discontinuations, it added.

The company also said a phase 3 trial comparing claseprubart at two dosing intervals against placebo is expected to begin in 2026.

Shares of the company were up over 5% in recent Monday premarket activity.